U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07186478) titled 'I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis' on Sept. 09.
Brief Summary: This study evaluates the potential of I-FALMIN, a supplement derived from toman fish (Channa micropeltes), as an additional source of albumin in patients with pulmonary tuberculosis. Tuberculosis patients often experience low albumin levels, which may slow down recovery. The purpose of this study is to determine whether giving I-FALMIN as a supplement, in addition to standard tuberculosis treatment, can improve albumin levels and support overall health status. The study will compare outcomes between patients who receive I-FALMIN and th...